Drug Profile
Research programme: Zika virus vaccine - CEVEC Pharmaceuticals/Lumos Pharma
Latest Information Update: 10 Oct 2022
Price :
$50
*
At a glance
- Originator CEVEC Pharmaceuticals; NewLink Genetics Corporation
- Developer CEVEC Pharmaceuticals; Lumos Pharma
- Class Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Zika virus infection